Voyager Therapeutics Inc (VYGR) — Cash Flow Reinvestment Rate

Latest as of March 2024: 1.67x

Voyager Therapeutics Inc (VYGR) has a Cash Flow Reinvestment Rate of 1.67x as of March 2024, reinvesting $98.21 Million (capex $2.14 Million plus investments $-96.06 Million) from operating cash flow of $58.77 Million. See VYGR cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.

Reinvestment Rate

1.67x
(Capex + Investments) / Operating CF

Total Reinvested

$98.21 Million
Capex + Investments

Operating Cash Flow

$58.77 Million
USD

Capital Expenditures

$2.14 Million
USD

Voyager Therapeutics Inc Cash Flow Reinvestment Rate (2015–2023)

Historical reinvestment intensity for Voyager Therapeutics Inc across 3 annual periods. For the full cash flow conversion analysis, see Voyager Therapeutics Inc cash flow conversion.

Annual Cash Flow Reinvestment Rate for Voyager Therapeutics Inc (2015–2023)

Year-by-year capital reinvestment analysis for Voyager Therapeutics Inc. See VYGR FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.

Year Reinvestment Rate Total Reinvested (USD) Operating CF Capex YoY Change
2023 1.86x $144.90 Million $77.92 Million $3.26 Million ▼ -0.2%
2019 1.86x $90.65 Million $48.67 Million $7.72 Million ▼ -60.5%
2015 4.72x $194.77 Million $41.30 Million $1.03 Million —
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow